HUP0104019A3 - Prophylactic use of n-methyl-d-aspartate (nmda) antagonists - Google Patents
Prophylactic use of n-methyl-d-aspartate (nmda) antagonistsInfo
- Publication number
- HUP0104019A3 HUP0104019A3 HU0104019A HUP0104019A HUP0104019A3 HU P0104019 A3 HUP0104019 A3 HU P0104019A3 HU 0104019 A HU0104019 A HU 0104019A HU P0104019 A HUP0104019 A HU P0104019A HU P0104019 A3 HUP0104019 A3 HU P0104019A3
- Authority
- HU
- Hungary
- Prior art keywords
- nmda
- aspartate
- antagonists
- methyl
- prophylactic use
- Prior art date
Links
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 title 2
- 239000005557 antagonist Substances 0.000 title 1
- 230000000069 prophylactic effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Biotechnology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US23732400P | 2000-10-02 | 2000-10-02 |
Publications (3)
Publication Number | Publication Date |
---|---|
HU0104019D0 HU0104019D0 (en) | 2001-12-28 |
HUP0104019A2 HUP0104019A2 (en) | 2002-06-29 |
HUP0104019A3 true HUP0104019A3 (en) | 2002-12-28 |
Family
ID=22893253
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0104019A HUP0104019A3 (en) | 2000-10-02 | 2001-10-01 | Prophylactic use of n-methyl-d-aspartate (nmda) antagonists |
Country Status (10)
Country | Link |
---|---|
US (1) | US20020072485A1 (hu) |
EP (1) | EP1199067A3 (hu) |
JP (1) | JP2002322092A (hu) |
KR (1) | KR20020027212A (hu) |
AU (1) | AU779152B2 (hu) |
CA (1) | CA2357925A1 (hu) |
HU (1) | HUP0104019A3 (hu) |
IL (1) | IL145685A0 (hu) |
NZ (1) | NZ514552A (hu) |
ZA (1) | ZA200108038B (hu) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7758890B2 (en) | 2001-06-23 | 2010-07-20 | Lyotropic Therapeutics, Inc. | Treatment using dantrolene |
GB0215389D0 (en) * | 2002-07-03 | 2002-08-14 | King S College London | Receptor |
JP4880449B2 (ja) | 2003-03-04 | 2012-02-22 | リオトロピック セラピュティックス アイエヌシー. | ダントロレンを用いる治療 |
DE10328260A1 (de) * | 2003-06-23 | 2005-01-27 | Schmidt, K.-G., Dr. med. | Flupirtine-Präparat |
US20080194698A1 (en) * | 2005-03-07 | 2008-08-14 | Michael Hermanussen | Nmda Receptor Antagonists in the Medical Intervention of Metabolic Disorders |
US8278355B2 (en) | 2006-09-12 | 2012-10-02 | Therexcell Pharma Inc. | Isovaline for treatment of pain |
WO2009105887A1 (en) * | 2008-02-26 | 2009-09-03 | Ernest Puil | Cyclic amino acids for the treatment of pain |
WO2010117170A2 (ko) * | 2009-04-06 | 2010-10-14 | 주식회사 뉴로테크 | 화상 손상의 치료 또는 예방용 약학 조성물 |
FR2948878B1 (fr) * | 2009-08-04 | 2012-08-31 | Air Liquide | Utilisation du xenon pour traiter l'hypersensibilite a la douleur |
US8648198B2 (en) | 2011-01-19 | 2014-02-11 | Cold Spring Harbor Laboratory | Phenylethanolamine-based NMDA receptor antagonists |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5710168A (en) * | 1991-10-23 | 1998-01-20 | Pfizer Inc. | 2-piperidino-1-alkanol derivatives as neuroprotective agents |
JP2866743B2 (ja) * | 1994-01-31 | 1999-03-08 | フアイザー・インコーポレイテツド | 神経保護化合物 |
EP0777652B1 (en) * | 1994-08-18 | 2003-06-25 | Pfizer Inc. | Neuroprotective 3-(piperidinyl-1)-chroman-4,7-diol and 1-(4-hydrophenyl)-2-(piperidinyl-1)-alkanol derivatives |
AU1463997A (en) * | 1995-12-22 | 1997-07-17 | Acea Pharmaceuticals, Inc. | Subtype-selective nmda receptor ligands and the use thereof |
ZA9610738B (en) * | 1995-12-22 | 1997-06-24 | Warner Lambert Co | Subtype selective nmda receptor ligands and the use thereof |
ZA9610745B (en) * | 1995-12-22 | 1997-06-24 | Warner Lambert Co | 4-Subsituted piperidine analogs and their use as subtype selective nmda receptor antagonists |
ZA9610741B (en) * | 1995-12-22 | 1997-06-24 | Warner Lambert Co | 4-Substituted piperidine analogs and their use as subtype selective nmda receptor antagonists |
ZA9610736B (en) * | 1995-12-22 | 1997-06-27 | Warner Lambert Co | 2-Substituted piperidine analogs and their use as subtypeselective nmda receptor antagonists |
GB9804885D0 (en) * | 1998-03-06 | 1998-04-29 | Merck Sharp & Dohme | Therapeutic combination |
GB9804886D0 (en) * | 1998-03-06 | 1998-04-29 | Merck Sharp & Dohme | Therapeutic combination |
AU3216600A (en) * | 1999-03-10 | 2000-09-28 | Warner-Lambert Company | Analgesic compositions comprising anti-epileptic compounds and methods of using same |
EP1186303A3 (en) * | 2000-09-06 | 2003-12-10 | Pfizer Products Inc. | Pharmaceutical combinations, for the treatment of stroke and traumatic brain injury, containing a neutrophil inhibiting factor and an selective NMDA-NR2B receptor antagonist |
IL145209A0 (en) * | 2000-09-06 | 2002-06-30 | Pfizer Prod Inc | Pharmaceutical combinations for the treatment of stroke and traumatic brain injury |
-
2001
- 2001-01-01 ZA ZA200108038A patent/ZA200108038B/xx unknown
- 2001-09-26 IL IL14568501A patent/IL145685A0/xx unknown
- 2001-09-28 CA CA002357925A patent/CA2357925A1/en not_active Abandoned
- 2001-09-28 EP EP01308289A patent/EP1199067A3/en not_active Withdrawn
- 2001-09-28 AU AU77305/01A patent/AU779152B2/en not_active Ceased
- 2001-09-29 KR KR1020010061004A patent/KR20020027212A/ko active Search and Examination
- 2001-10-01 NZ NZ514552A patent/NZ514552A/en unknown
- 2001-10-01 HU HU0104019A patent/HUP0104019A3/hu unknown
- 2001-10-02 US US09/969,354 patent/US20020072485A1/en active Pending
- 2001-10-02 JP JP2001306332A patent/JP2002322092A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
US20020072485A1 (en) | 2002-06-13 |
ZA200108038B (en) | 2003-04-01 |
EP1199067A3 (en) | 2003-03-26 |
NZ514552A (en) | 2004-10-29 |
CA2357925A1 (en) | 2002-04-02 |
EP1199067A2 (en) | 2002-04-24 |
AU779152B2 (en) | 2005-01-06 |
IL145685A0 (en) | 2002-06-30 |
JP2002322092A (ja) | 2002-11-08 |
AU7730501A (en) | 2002-04-11 |
KR20020027212A (ko) | 2002-04-13 |
HU0104019D0 (en) | 2001-12-28 |
HUP0104019A2 (en) | 2002-06-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1390034A4 (en) | NMDA / NR2B NONARYL-HETEROCYCLO AMIDYL N-SUBSTITUTE ANTAGONISTS | |
PL365377A1 (en) | Amide derivatives as nmda receptor antagonists | |
IL223673A0 (en) | Once-a-day oxycodone formulation | |
AP2002002617A0 (en) | Tamper-resistant oral opioid agonist formulation | |
GB2366948B (en) | LAN user protocol | |
IL155810A0 (en) | Nmda receptor agonist pharmaceutical compositions | |
HU0104019D0 (en) | Prophylactic use of n-methyl-d-aspartate (nmda) antagonists | |
AU2001286409A1 (en) | N-methyl-d-aspartate receptor antagonists | |
EP1296958A4 (en) | ANTIAGONISTS OF NMDA NR2B RECEPTORS OF IMINOPYRIMIDINE | |
IL129187A0 (en) | NMDA (N-methyl-D-aspartate) antagonists | |
HUP0303418A3 (en) | Inhibitors of papilloma virus | |
CA97201S (en) | Napkin | |
AU9620901A (en) | Dynamic impedance comparator | |
AU1046702A (en) | New use | |
HK1054508A1 (zh) | 新型製劑 | |
GB0004183D0 (en) | New use | |
AU2002333369A1 (en) | Substituted octahydrophenanthrene compounds and their use as nmda antagonists | |
GB2369445B (en) | Component measures | |
TW543870U (en) | Mouse capable of indicating when moving | |
GB0017448D0 (en) | Elbow platform (bathing) | |
CA94023S (en) | Napkin | |
GB0015054D0 (en) | Prophylactic | |
GB0021951D0 (en) | Stick-down prophylactic | |
GB0111833D0 (en) | Dual-labelled probes | |
GB0009125D0 (en) | Antagonists |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD9A | Lapse of provisional protection due to non-payment of fees |